

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

KVK-TECH, INC.,

Petitioner,

v.

SHIRE LLC,

Patent Owner.

Case IPR2018-00293
US Patent No. 9,173,857

DECLARATION OF JAMES E. POLLI, Ph.D.

SHIRE EX2060
KVK v. SHIRE
IPR2018-00293

TABLE OF CONTENTS

	Page
LIST OF EXHIBITS	iii
I. INTRODUCTION	1
II. EXPERIENCE AND QUALIFICATIONS.....	1
A. Professional Background.....	1
B. Materials Considered for This Declaration	3
III. SUMMARY OF MY OPINION.....	4
IV. LEGAL PRINCIPLES.....	5
A. Claim Construction.....	5
B. Anticipation and Obviousness.....	7
C. Person of Ordinary Skill in the Art	10
V. THE CHALLENGED PATENT	12
VI. PRINCIPLES OF DRUG DELIVERY	17
A. Dissolution, Absorption, Distribution and Therapy.....	17
B. Predictability in Drug Formulation Requires Observed Data- Based Modeling.....	22
VII. THE PTAB DECISION TO INSTITUTE THESE PROCEEDINGS	31
VIII. THERE IS NO PRIOR ART IN VITRO/IN VIVO CORRELATION OR PK/PD MODEL IN EVIDENCE – THERE CANNOT BE ANY REASONABLE EXPECTATION OF SUCCESS FOR THE INTENDED PURPOSE	41
A. Burnside’s In Vitro Dissolution Test Did Not Indicate In Vivo Results	41
B. The Prior Art Discloses No Information or Data that Would Motivate a Three Bead IR-DPR-SR Amphetamine Combination Formulation with any Reasonable Expectation of Success	45
1. Burnside Discloses No Information or Data that Would Motivate a Three Bead IR-DPR-SR Combination Formulation with any Reasonable Expectation of Success	45

TABLE OF CONTENTS

(continued)

	Page
2. The ADDERALL XR PDR and Label Disclose No Information or Data that Would Motivate a Three Bead IR-DPR-SR Combination Formulation with any Reasonable Expectation of Success	54
3. Speculation from the Principle of Superposition Would Not Yield a Reasonable Expectation of Success from a Hypothetical Burnside Combination	58
IX. THE PRIOR ART TAUGHT AWAY FROM SUSTAINED RELEASE FOR A THERAPEUTIC AMPHETAMINE COMPOSITION	74
A. Acute Tolerance Made It Impossible to Have any Reasonable Expectation of Success in Using an SR Bead with Amphetamines to Treat Disease.....	74
B. Collectively, Other References Relied on by Petitioner Support an Expectation that Sustained Release Would Likely Fail	83
C. Additional References Support an Expectation that Sustained Release Would Likely Fail.....	89
X. CLAIMS 5-12 AND 21 ARE NOT OBVIOUS OVER BURNSIDE ALONE OR WITH ADDERALL XR (“THE PK CLAIMS”)	93
A. Claims 5-12 Are Not Obvious over Burnside Alone or with Adderall XR ("The PK Claims").....	94
1. Different Bead and Dose Ratios Produce Different Results.....	94
2. Different Coating Thicknesses Produce Different Results	98
B. Claim 19 (No Food Effect).....	100
XI. CLAIMS 20-28 ARE NOT OBVIOUS ("DOSAGE CLAIMS")	103
APPENDIX A CURRICULUM VITAE	

LIST OF EXHIBITS

2001	DECLARATION OF BERNHARDT L. TROUT, Ph.D. (with CV)
2002	DECLARATION OF SARA ROSENBAUM, Ph.D. (with CV)
2003	FDA Orange Book Listing for MYDAYIS® (NDA N022063)
2004	MYDAYIS® FDA Label (06-2017)
2005	MYDAYIS® Website Pages
2006	Amidon, U.S. Patent No. 5,229,131
2007	Mehta, U.S. Patent No. 5,837,284
2008	IPR2017-00011 Decision Denying Institution (RE41, 148) (300 Patent)
2009	Excerpts from Merck, 11th Ed
2010	Ansel, Popovich & Allen 6th, Ch. 3-5 (1995)
2011	Sonsalia, Remington Ch. 74, - CNS Stimulants (1995)
2012	Robinson, Remington, Ch. 94 - Sustained Release (1995)
2013	Porter, Remington, Ch. 93 – Coating (1995)
2014	Franz, Remington Vol. II, Ch. 57 - Sympathomimetic Drugs (1995)
2015	Malinowski, Remington, Ch. 53 – Bioequivalence (2000)
2016	Stempel, 7th Ed. - Dispensing of Medication (1971)
2017	USP 23 NF 18 - Uniformity Sec. 905 (1955)
2018	USP 23 NF 18 1995 - Excerpts (1955)
2019	Patrick, Human Psychopharmacology, 12:527-546 (1997)
2020	Spencer, Arch Gen Psych, 58:775-78 (2001 Aug)
2021	Lehninger, Principles of Biochemistry, Excerpt (1993)
2022	Benet, Toxicologic Pathology, 23:115-123 (1995)
2023	Shargel, Applied Bio & Pharmacokinetics, Ch. 2, 10 (1999)
2024	Gibaldi, Biopharmaceutics & Clinical Pharmacokinetics, Ch.1 (1991)
2025	Gibaldi, Biopharmaceutics & Clinical Pharmacokinetics, Ch.5 (1991)
2026	Chiao, Remington, Ch. 94 – Sustained Release (1995)
2027	Hinsvark, J. Pharmacokin. Biopharm., 1:319-328 (1973)
2028	Benet, Transplantation Proc., 31 (Suppl 3A), 7S-9S (1999)

2029	Winters, Basic Clinical Pharmacokinetics (1994)
2030	Rowland, Clinical Pharmacokinetics 2d (1989)
2031	Mircioiu, Basic & Clinical Pharmacology & Toxicology, 96:262–264 (2005)
2032	Booijink, Future Microbiol. 2(3), 285-295 (2007)
2033	Fischer, Pharm. Res., 4:480-485 (1987)
2034	Gupta and Robinson, Controlled Release Delivery (1992)
2035	Macheras, Oral Drug Absorption, Ch. 6 - Modeling Biopharm. (2006)
2036	Schug, European J. Pharm. Sci., 15:279-285 (2002)
2037	Hendeles, J. Allergy Clin. Immunol., 72:7:43-751 (1986)
2038	FDA Use & Limitations of In Vitro Testing (Excerpts)
2039	Guidance for Industry ER Formulations IVIVC (1997)
2040	Amidon, Mol. Pharm., 7:1361 (2010)
2041	Khan, International Journal of Pharmaceutics 140:131-143 (1996)
2042	Koziolk, Advanced Drug Delivery Reviews 101:75–88 (2016)
2043	Chasseaud, Ann. Rev. Pharmacol., 14:35-46 (1974)
2044	Greenhill, J. Am. Acad. Child Adolesc. Psychiatry, 42:1234-1241 (2003)
2045	Swanson, Clin. Pharmacol. Therap., 66:95-305 (1999)
2046	Spencer, Current Diagn & Treatment Psych., Ch 35 – ADHD (2008)
2047	Decision re Institution of IPR2015-02009
2048	Gibaldi, Biopharmaceutics & Clinical Pharmacokinetics, Ch. 7 – (1991)
2049	Gibaldi, Biopharmaceutics & Clinical Pharmacokinetics, Appendix II (1991)
2050	Percel, US 2003-0157173A1
2051	Couch, WO 2004-028509A1
2052	Shire, Q3 2017 MYDAYIS Results (Excerpts)
2053	Brauer, J. Clin. Pharm. 16-1, 72-76 (1996)
2054	Shire, ER and IR Utilization in Adult ADHD [CONFIDENTIAL]
2055	Shire, MYDAYIS Performance [CONFIDENTIAL]
2056	Auiler, Curr. Med. Res. Opin., 18:311-316 (2002)
2058	Ansel, Popovich & Allen 6th, Ch. 3-5 (1995) (EX2010 CORRECTED)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.